



Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, February 5, 2013:

Unaudited Financial Results for Q 3- 2012-13

J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its standalone unaudited financial results for the quarter ended on December 31, 2012. The company has achieved encouraging performance during Q3 due to higher sales and favourable product mix. The highlights of the Y-o-Y results are as under:

(Rs. in crores)

| Particulars | Q3 | | 9 Months | |
|--|---------|---------|----------|---------|
| | 2012-13 | 2011-12 | 2012-13 | 2011-12 |
| Sales (Net) | 199.76 | 149.55 | 596.73 | 487.77 |
| Other income | 11.53 | 12.12 | 37.94 | 67.92 |
| Total Revenue | 211.29 | 161.67 | 634.67 | 555.69 |
| Profit from ordinary activities after finance cost but before exchange fluctuation translation gain/loss | 24.49 | 9.28 | 78.35 | 81.29 |
| Profit from ordinary activities before exceptional item | 31.24 | (18.31) | 84.91 | 40.63 |
| Exceptional item | --- | --- | --- | 760.59 |
| Profit before tax | 31.24 | (18.31) | 84.91 | 801.22 |
| Profit after tax | 21.87 | (5.17) | 65.19 | 633.83 |
| EPS (Rs.) | 2.58 | (0.61) | 7.70 | 74.90 |
| Book value per share (Rs.) | 120.30 | | 120.30 | |

The overall operating revenues for the quarter were 33.57% higher over the corresponding quarter in the previous year. The profit from operations (after finance cost but before foreign exchange translation gain) for the quarter at Rs. 24.49 crores registered impressive growth of 163.90%. The profit from operations for nine months ended December 2011 included dividend of Rs. 24.97 crores received from the Russian subsidiary. If the same is removed, then the profit from operations during the nine months ended December 2012 shows growth of 39.12%.

All businesses of the company registered growth during the quarter. The domestic formulations business achieved marginal growth but actively promoted products achieved good growth of 15 %.

The exports to Rest of the World markets achieved good growth of 11% in sales in \$ terms over the same quarter last year. The exports of prescription products to Russia-CIS markets continued to grow during the quarter. The company believes that its Rx portfolio has good potential in this market and would continue to invest in new products and infrastructure for future growth.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and API's. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine, CIS countries and South Africa. The Company continues to invest in growing its share in the regulated markets in USA, Europe, Australia and Brazil. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMF's and ANDA's. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta
Company Secretary- General Manager
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 3045 1311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.